Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy.

The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate the efficacy, safety and tolerability of three dose levels of AEG33773 in diabetic patients suffering from significant neuropathic pain. This study is underway in Canada and Aegera will soon initiate trial sites in the Unites States, where the IND has recently cleared the FDA regulatory review process, and also in Europe, where the regulatory documents are now under review by the appropriate regulatory authorities.

"We are very excited about this first Phase 2 study for AEG33773 which has demonstrated robust preclinical in vivo data in multiple models of neuropathic and inflammatory pain. Furthermore, AEG33773 could have the potential to treat chronic pain conditions well beyond painful diabetic neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President Clinical Development of Aegera.

"With the successful conclusion of the Phase 1 safety studies for AEG33773 and the initiation of the first Phase 2a trial in diabetic patients suffering from significant neuropathic pain, we are now focused on successfully completing this trial while identifying an appropriate development partner; this will ensure that our novel agent is developed rapidly and effectively for its first indication while exploring additional indications so as to expand this franchise on a global basis." added Dr. Michael J. Berendt, Aegera's President and CEO.

About Aegera Therapeutics Inc. (www.aegera.com'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Texas Fertility Center ... in South Austin, expanding a Central Texas footprint that ... Antonio. The satellite office for the region’s most established ... to the South Austin, Buda, Kyle and San Marcos ... affordable fertility treatment directly to individuals and couples living ...
(Date:9/23/2014)... Dr. Williams says, “Find The Black Box ( ... three phase process that can lead to the creation ... go far beyond anything previously imagined. First everyone must ... , “Every effort to improve the quality of healthcare ... throughout that system because all of the experts have ...
(Date:9/23/2014)... September 23, 2014 The Minnesota ... developer of cellular modems , platforms and ... the Startup category for the 2014 Tekne Awards. ... at the Minneapolis Convention Center on Thursday, November ... individuals who have shown superior technology innovation and ...
(Date:9/22/2014)... Calif., September 22, 2014 Patients who were treated with ... hemorrhagic stroke were significantly more likely to survive than ... today in JAMA Neurology . This study was ... the use of cholesterol-lowering statins can improve survival in ... a constriction or obstruction of a blood vessel that ...
Breaking Biology Technology:Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2
... DALLAS, Texas , June 15, 2010 ... Brazil , Russia , India , China (BRIC)" published by ... million in 2009 and is expected to reach $570.56,million in ... , , ...
... , ... filed alleging that the DePuy ASR hip replacement was defectively designed and that DePuy did ... , ... A lawsuit has been filed against hip replacement manufacturer DePuy Orthopaedics, Inc over failure of ...
... type of baker,s yeast ( Saccharomyces cerevisiae ) has ... found in agricultural waste and hardwoods. Researchers writing in ... describe the creation of the new S. ... growth rate and final biomass concentration on sugar media ...
Cached Biology Technology:Diabetes Care Devices Market In Brazil, Russia, India, China (BRIC) Worth $570.56 Million In 2014 2Diabetes Care Devices Market In Brazil, Russia, India, China (BRIC) Worth $570.56 Million In 2014 3Diabetes Care Devices Market In Brazil, Russia, India, China (BRIC) Worth $570.56 Million In 2014 4First DePuy ASR Hip Replacement Lawsuit Filed in the US 2
(Date:9/22/2014)... image burn in Khabarovsk Krai, a territory occupying the coastline ... by plumes of smoke mark active fires. The smoke, which ... the Sea of Okhotsk. Taiga and tundra are ... the central depression, and deciduous forests are the natural vegetation ... Russia in the summer, the 2014 wildfire season appears to ...
(Date:9/22/2014)... could be much more useful in homes, if they ... see the world with cameras and lasers, which have ... are hidden in clutter. A complementary way robots can ... of small ultra-high frequency radio-frequency identification (UHF RFID) tags. ... an RFID-equipped robot to search a room for the ...
(Date:9/22/2014)... greater risk for stress-related diseases like type 2 ... new study by Brandeis University. , It,s long ... similar to the effects of illness or injury, ... part of our body,s healing response, runaway inflammation ... , In a recently published paper in ...
Breaking Biology News(10 mins):New RFID technology helps robots find household objects 2New RFID technology helps robots find household objects 3Obesity and stress pack a double hit for health 2
... majority of the abstracts to be presented at the EORTC-NCI-AACR [1] ... two weeks before the meeting at 00.01 hrs CET on Friday ... Journalists are free to report on the online abstracts from ... they should bear in mind that all the abstracts had to ...
... Richmond, Va. (Oct. 27, 2010) If you ... A recent study conducted by researchers from Virginia Commonwealth ... cancer patients who were eligible for genetic testing never ... relative,s life. The research, "Exploring Hereditary Cancer ...
... SHORES, Calif., Oct. 27 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
Cached Biology News:Abstracts for the EORTC-NCI-AACR Symposium in Berlin go up online on Friday, Oct. 29 2Knowledge of genetic cancer risks often dies with patients, finds VCU Massey Cancer Center 2CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 2CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 3CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 4CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 5CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 6CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 7CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 8CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 9CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 10
... reduce the chance of error. Thats the ... using Beckman Coulters extensive experience in laboratory ... the CEQ 8000 is a fully automated ... the capillary array with a patented linear ...
... The CHEMICON MDR1 Shift Assay provides a convenient ... occur upon transport of MDR1 substrates. Thus, the ... to which small molecules act as transport substrates ... in the presence of MDR1 substrates, the MDR1 ...
... Chemicon Detergent-OUT SDS Kit is a simple ... protein solutions. Removes detergents without significant ... the protein solution on the Detergent-OUT Spin ... Med columns are suitable for removing ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5 mm ...
Biology Products: